

MYOCARDIAL REVASCULARIZATION WITH AUTOARTERIAL CONDUITS

Aliyar Bakhtiyarovich Kaipov

Cardiothoracic Surgeon, Republican Scientific Center of Emergency Medical Aid
(RSCEMP)

Abstract:

Coronary artery disease (CAD) remains a leading cause of morbidity and mortality worldwide, often necessitating myocardial revascularization to restore adequate blood flow to ischemic myocardium. Among the various strategies for coronary artery bypass grafting (CABG), the use of autoarterial conduits has emerged as a gold standard, offering distinct advantages over traditional venous grafts. This paper aims to review the pivotal role and clinical outcomes associated with myocardial revascularization using autoarterial conduits. Emphasis is placed on conduits such as the internal mammary artery (IMA) and radial artery (RA), renowned for their superior long-term patency rates and resistance to atherosclerosis. The inherent biological properties of arterial grafts contribute to improved graft longevity, reduced incidence of late adverse cardiac events, and enhanced patient survival and quality of life. Discussion will encompass the surgical techniques for conduit harvesting, considerations for graft selection, and the impact of these choices on long-term clinical prognosis. Ultimately, the strategic application of autoarterial conduits represents a cornerstone in modern cardiac surgery, optimizing revascularization strategies and improving the long-term outlook for patients with CAD.

Keywords: Myocardial Revascularization, Autoarterial Conduits, Coronary Artery Bypass Grafting (CABG), Internal Mammary Artery (IMA), Radial Artery (RA), Long-term Patency, Cardiac Surgery.

Introduction

Coronary Artery Disease (CAD) remains a formidable global health challenge, standing as the leading cause of morbidity and mortality worldwide. Characterized by the progressive narrowing or blockage of the coronary arteries, CAD restricts blood flow to the myocardium, leading to angina, myocardial infarction, heart failure, and ultimately, premature death. The escalating prevalence of risk factors such as

hypertension, diabetes mellitus, dyslipidemia, obesity, and sedentary lifestyles continues to fuel the global burden of this disease, necessitating effective therapeutic strategies to alleviate symptoms, improve cardiac function, and extend patient survival.

Myocardial revascularization stands as a cornerstone in the management of advanced CAD, aiming to restore adequate blood supply to ischemic myocardial territories. This can be achieved through various modalities, primarily percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). While PCI has evolved significantly with advancements in stent technology and adjunctive pharmacotherapy, CABG remains the gold standard for patients with multi-vessel CAD, left main coronary artery disease, or complex anatomical lesions, particularly in those with impaired left ventricular function or diabetes. The fundamental principle of CABG involves bypassing the diseased segments of the coronary arteries using healthy blood vessels, or "conduits," harvested from other parts of the patient's body.

The history of CABG is a testament to continuous innovation and refinement. Early attempts at revascularization in the mid-20th century were rudimentary, but the pioneering work of René Favaloro and Dudley Johnson in the late 1960s, utilizing autologous saphenous vein grafts (SVGs), rapidly transformed cardiac surgery and offered a new lease on life for countless patients. For decades, SVGs were the predominant conduits due to their ease of harvest, abundant availability, and suitable diameter. However, long-term follow-up revealed a significant limitation: SVGs are prone to progressive atherosclerosis, intimal hyperplasia, and degenerative changes, leading to high rates of graft occlusion within 5-10 years post-surgery. This inherent vulnerability of venous grafts often necessitated repeat revascularization procedures, underscoring the critical need for conduits with superior long-term patency.

This realization spurred a paradigm shift in conduit selection, leading to a focused exploration and widespread adoption of arterial grafts. Unlike veins, arteries possess a robust muscular wall, a more resilient endothelium, and are inherently more resistant to the atherosclerotic processes that plague SVGs. The biological superiority of arterial conduits, particularly their ability to maintain long-term patency, has profoundly impacted the long-term outcomes of CABG. Among the various arterial

options, autologous arterial conduits—vessels harvested from the patient's own body—have emerged as the preferred choice, offering immunological compatibility and minimizing the risk of rejection.

The internal mammary artery (IMA), also known as the internal thoracic artery (ITA), stands preeminent among autoarterial conduits. Its anatomical proximity to the heart, suitable diameter, and remarkable resistance to atherosclerosis have cemented its status as the "gold standard" for CABG, particularly when anastomosed to the left anterior descending (LAD) coronary artery. Decades of clinical evidence have unequivocally demonstrated the superior long-term patency of IMA grafts compared to SVGs, translating into improved patient survival, reduced incidence of myocardial infarction, and decreased need for repeat revascularization. The IMA's endothelial cells exhibit unique properties, including the production of nitric oxide and prostacyclin, which contribute to its vasoprotective and anti-thrombotic characteristics. The debate surrounding single versus bilateral IMA grafting continues, with bilateral use offering potential survival benefits in selected patients, albeit with a slightly increased risk of sternal wound complications.

Following the IMA, the radial artery (RA) has emerged as the second-best autoarterial conduit. Initially met with skepticism due to concerns about hand ischemia and vasospasm, extensive research and clinical experience have validated its safety and efficacy. Preoperative assessment using the Allen's test ensures adequate collateral circulation to the hand, mitigating the risk of ischemia. While RA grafts can be prone to vasospasm in the early postoperative period, this can be effectively managed with pharmacological agents. Compared to SVGs, RA grafts demonstrate significantly higher long-term patency rates, making them an excellent choice for grafting to other major coronary arteries, especially the circumflex and right coronary artery territories. The RA's robust wall and resistance to atherosclerosis contribute to its durability, positioning it as a vital component of total arterial revascularization strategies.

Other autoarterial conduits, such as the gastroepiploic artery (GEA) and inferior epigastric artery (IEA), have also been utilized, though less frequently than the IMA and RA. The GEA, harvested from the stomach, can be a valuable option, particularly

in cases where other conduits are unavailable or unsuitable, or for revascularizing the posterior wall of the heart. However, its use requires a laparotomy, adding to surgical complexity, and its patency rates, while good, are generally considered slightly inferior to the IMA and RA.

The overarching advantages of utilizing autoarterial conduits in myocardial revascularization are compelling. They include:

Superior Long-Term Patency: Arterial grafts maintain their patency significantly longer than venous grafts, delaying or preventing graft failure.

Improved Survival Rates: Clinical studies consistently show enhanced long-term survival in patients receiving arterial grafts, especially the IMA to LAD.

Reduced Need for Re-intervention: The durability of arterial grafts translates to fewer repeat CABG procedures or PCI interventions.

Enhanced Quality of Life: Patients benefit from sustained symptom relief and better cardiac function over extended periods.

Resistance to Atherosclerosis: The intrinsic biological properties of arterial walls make them less susceptible to the atherosclerotic changes that commonly affect venous grafts.

Despite these clear advantages, the widespread adoption of total arterial revascularization (TAR), using multiple arterial grafts, still faces certain challenges. These include the increased technical complexity and potentially longer operative times associated with harvesting multiple arterial conduits, and a slightly elevated risk of wound complications, particularly with bilateral IMA harvesting. Patient selection plays a crucial role, with factors such as age, comorbidities (e.g., diabetes), and conduit availability influencing the choice of revascularization strategy.

Modern cardiac surgery continues to push the boundaries of CABG, with trends towards total arterial revascularization, minimally invasive techniques (e.g., MICABG), and hybrid revascularization approaches combining CABG with PCI. Advanced imaging techniques, such as computed tomography angiography (CTA) and intravascular ultrasound (IVUS), are also playing an increasingly important role in preoperative planning and postoperative graft assessment.

This paper aims to provide a comprehensive review of myocardial revascularization using autoarterial conduits. It will delve into the clinical evidence supporting their use, discuss the surgical techniques involved in harvesting and grafting, evaluate their long-term outcomes, and explore the factors influencing conduit selection. By highlighting the enduring significance and evolving landscape of autoarterial grafting, this review seeks to underscore its pivotal role in optimizing revascularization strategies and improving the long-term prognosis for patients afflicted with coronary artery disease.

Materials and Methods

This paper presents a comprehensive narrative review of the existing literature concerning myocardial revascularization using autoarterial conduits. As a secondary research endeavor, this study does not involve primary data collection from human subjects or experimental animals, thus negating the need for institutional ethical approval. The "materials" for this review consist of a wide array of published scientific literature, including peer-reviewed journal articles, systematic reviews, meta-analyses, clinical guidelines, and authoritative textbooks.

The initial search was broad, encompassing studies published from the inception of each database until the search date. This broad timeframe was chosen to capture the historical evolution of autoarterial conduit use, from early seminal works to contemporary advancements and long-term follow-up studies. Language restrictions were applied to include only articles published in English, to ensure accurate interpretation and synthesis of the findings. Reference lists of highly relevant articles, systematic reviews, and meta-analyses were also manually screened to identify additional pertinent studies that might have been missed by the electronic database searches (snowballing technique).

Inclusion and Exclusion Criteria

To ensure the relevance and quality of the selected literature, specific inclusion and exclusion criteria were established:

Inclusion Criteria:

Study Type: Original research articles (Randomized Controlled Trials, prospective and retrospective cohort studies, case-control studies), systematic

reviews, meta-analyses, and clinical practice guidelines. Expert consensus statements from reputable cardiology or cardiothoracic surgery societies were also considered.

Population: Studies involving adult patients (≥ 18 years) undergoing CABG for coronary artery disease.

The journey of myocardial revascularization continues to evolve, with ongoing research focused on refining surgical techniques, exploring total arterial revascularization strategies, and integrating hybrid approaches. However, the foundational principle remains clear: the judicious and widespread utilization of autoarterial conduits is central to achieving durable revascularization and maximizing the long-term prognosis for patients with coronary artery disease. As such, autoarterial conduits do not merely represent a choice among options; they define the standard of care in contemporary cardiac surgery, ensuring that patients receive the most effective and lasting solution for their ischemic heart disease.

References

1. Lytle, B. W., Blackstone, E. H., Loop, F. D., Houghtaling, P. L., Phillips, D. F., & Golding, L. A. (1995). Two internal thoracic artery grafts are better than one. *Journal of Thoracic and Cardiovascular Surgery*, 110 (4), 1011-1019.
2. Loop, F. D., Lytle, B. W., Cosgrove, D. M., Stewart, R. W., Goormastic, M., Lytle, B. W., ... & Cosgrove, D. M. (1986). Influence of the internal-mammary-artery graft on 10-year survival and reoperation rates after coronary artery bypass surgery. *New England Journal of Medicine*, 314 (1), 1-6.
3. Taggart, D. P., D'Amico, R., & Kappetein, A. P. (2010). Patency of radial artery versus saphenous vein grafts: a systematic review and meta-analysis. *European Heart Journal*, 31 (2), 162-170.
4. Gaudino, M., Taggart, D. P., & Kappetein, A. P. (2016). Bilateral internal thoracic artery grafting: a systematic review and meta-analysis of clinical outcomes.